InspireMD Q3 Revenue Falls 11.1% to $2.24M; Cash Drops to $19.2M Ahead of TCAR Launch
NSPR sits 53% above its 52-week low of $0.425 on elevated volume (4.9× avg).
Summary
InspireMD's Q3 revenue fell 11.1% to $2.24M as U.S. sales dried up after the recall, and cash fell to $19.2M from $54.2M at year-end. The FDA's TCAR approval is the offset, with U.S. sales expected to start in Q4 2026.
Key Events · Earnings and Guidance · NSPR
-
Q3 Revenue Falls 11.1% on Recall
Total revenue was $2,242,000 versus $2,523,000 a year ago. U.S. revenue collapsed to $32,000 from $497,000 after the May 2026 CGuard Prime for CAS delivery-system recall, while international revenue rose 9.1% to $2,210,000.
-
Gross Margin Collapses to 10.7%
Gross profit was $240,000, or 10.7% of revenue, versus $864,000, or 34.2%, a year earlier, driven by the recall and a shift in international mix to lower-average-selling-price countries.
-
Cash Falls to $19.2M From $54.2M
Cash, cash equivalents and marketable securities totaled $19,246,000 at September 30, 2026, versus $54,211,000 at December 31, 2025, against a nine-month net loss of $37,775,000.
-
FDA TCAR Approval Sets Up Q4 Launch
The FDA approved CGuard Prime for TCAR procedures, which the company says adds over 35,000 procedures annually to its addressable market; U.S. sales are expected to commence promptly in Q4 2026.
Analysis · NSPR · Industrial Applications And Services
The cash position is the real story here. Revenue fell to $2,242,000 from $2,523,000 a year ago, as U.S. sales collapsed to $32,000 from $497,000 following the May 2026 recall of the CGuard Prime for CAS delivery system. Gross margin fell to 10.7% from 34.2%, and the net loss was $9,762,000. Cash and marketable securities stood at $19,246,000 at September 30 versus $54,211,000 at December 31, 2025, against a nine-month net loss of $37,775,000. That burn rate means the company will need to raise money again, and it already has a $75M ATM program in place. The offset is the November 12 FDA approval of CGuard Prime for TCAR, which the company says expands the addressable market by over 35,000 procedures annually and should start generating U.S. sales in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NSPR was trading at $0.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.